World Health Organization, South-East Asia Regional Office
Vol. 21, Week 44, 2017
Published 06 November 2017
Meetings/ Important events:
Tenth Meeting of the South-East Asia Regional Commission for the Certification of Polio Eradication (SEA-RCCPE), Naypitaw, Myanmar,
23-24 November 2017
Table 1: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2017* (data as of 06 November 2017)
Case classification (number)
Pending classification
Epidemiologicallyconfirmed
Reporti ng
% di s tri cts
ra te of
reporti ng a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
n
non-rubel l a
pop
pop n
na ti ona l
ca s es per
l evel per
100,000 pop n
100,000 pop n
Laboratory-confirmed
Discarded non-measles nonrubella cases
Rubel l a
Clinically-confirmed
% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory
Mea s l es
Epidemiologicallyconfirmed
Number of
s erum
s peci mens
recei ved i n
l a bora tory
% s erum
s peci mens
recei ved a t
l a bora tory
w/i n 5
da ys of
col l ecti on
%
s peci mens
tes ted for
s erol ogy
of
s peci mens
recei ved
i n the
l a bora tory
Laboratory-confirmed
%
s us pected
ca s es wi th
%
Number of a dequa te s us pected
s us pected i nves ti ga ti ca s es wi th
on
mea s l es
s erum
i ni ti a ted s peci mens
ca s es
w/i n 48
col l ected
hours of
noti fi ca ti on
7 418
92
80
5 971
99
100
60
2 491
906
444
209
34
3 334
0
2.53
73
29.10
1.84
221
84
79
166
59
105
46
14
0
0
2
0
160
45
25.38
65
22.20
3.17
DPR Korea
63
100
100
63
100
100
100
0
0
0
0
0
63
0
0.30
0.00
0.00
3
16 200
0
33
5 106
80
85
57
2 326
6 158
0
696
2 004
2 482
2 534
0.23
5
7.92
2.52
4.53
2.60
Countries
Bangladesh
Bhutan
India
4
4 793
38
100
3 531
92
73
27
967
0
0
554
0
497
2 775
0.23
Maldives
62
97
100
62
100
100
69
1
0
0
1
0
59
1
20.40
60
3.46
3.46
Myanmar
1 645
40
88
1 443
99
100
94
994
179
70
3
0
374
25
0.86
14
28.57
0.07
Nepal
713
26
89
232
74
257
84
51
26
21
14
0
571
23
2.47
51
4.24
0.61
Sri Lanka
203
98
89
177
90
100
62
1
0
18
1
0
183
0
1.05
23
62.00
0.42
Thailand
2 381
31
91
2 080
56
96
60
1 281
4
296
23
0
695
82
1.27
28.80
0.42
98
100
99
97
100
87
64
0
0
0
3
0
82
13
8.00
33 797
32
62
18 928
87
92
56
8 126
7 273
849
1 506
2 038
8 500
5 498
0.46
Indonesia
Timor-Leste
SEAR
1
Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases
2
Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases
4
31
A lso includes the cases fro m enhanced measles case-based surveillance.
0.00
2.93
10.30
2.25
ND=No data
3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry
* Figures in the table 1 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.
Table 2: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2016* (data as of 06 November 2017)
Case classification (number)
India 3
4
Pending classification
Discarded non-measles nonrubella cases
Reporting
% di s tri cts
ra te of
reporting a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
n
n
non-rubel l a
pop
pop
na tiona l
ca s es per
l evel per
n
100,000 pop
100,000 pop n
4 298
94
87
3 732
100
100
92
619
354
96
165
0
3 064
0
1.96
80
6.85
1.06
149
63
87
127
59
102
47
10
0
0
0
0
60
79
8.05
55
13.42
0.00
73
100
100
73
100
100
100
0
0
0
0
0
66
7
0.27
0.00
0.00
41 617
0
22
9 037
86
83
31
3 646
12 803
0
1 617
7 539
6 998
9 014
0.55
3
13.00
7.24
10.73
4.50
Epidemiologicallyconfirmed
Laboratory-confirmed
DPR Korea
Rubel l a
Clinically-confirmed
Bhutan
% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory
Mea s l es
Epidemiologicallyconfirmed
Bangladesh
Number of
s erum
s peci mens
recei ved i n
l a bora tory
% s erum
s peci mens
recei ved a t
l a bora tory
w/i n 5
da ys of
col l ection
%
s peci mens
tes ted for
s erol ogy
of
s peci mens
recei ved
i n the
l a bora tory
Laboratory-confirmed
Countries
%
s us pected
ca s es wi th
%
Number of a dequa te s us pected
s us pected i nves tiga ti ca s es wi th
on
s erum
mea s l es
i ni tia ted s peci mens
ca s es
w/i n 48
col l ected
hours of
notifi ca tion
8 107
44
100
5 871
98
74
32
2 705
0
0
1 135
0
2 361
1 906
0.94
Maldives
11
100
100
11
100
0
0
0
0
0
0
0
11
0
3.22
15
0.00
0.00
Myanmar
587
0
86
503
100
99
97
194
59
21
10
0
303
0
0.59
11
5.33
0.19
Indonesia
5
1 079
13
82
1
100
0
137
102
31
22
0
772
15
2.83
56
9.89
0.81
Sri Lanka
339
63
86
291
88
100
68
64
0
48
1
0
226
0
1.09
27
62.00
0.42
Thailand
1 431
25
87
1 096
61
99
58
695
15
239
7
0
415
60
0.64
14.63
0.11
122
75
91
111
100
95
63
2
0
11
9
0
100
0
8.25
46
10.73
7.43
57 813
15
42
20 853
91
89
46
8 072
13 333
446
2 966
7 539
14 376
11 081
0.77
11.72
5.63
Nepal
Timor-Leste
SEAR
1
Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases
4
A lso includes the cases fro m enhanced measles case-based surveillance.
2
Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases
5
So me Lab data variables no t available.
ND=No data
3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry
* Figures in the table 2 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.
Data Sources: Ministries of Health in SEAR Countries.
Published by Immunization & Vaccine Development, World Health Organization, Regional Office for South-East Asia, New Delhi – 110002, India
Tel: 91-11-2337-0804 / 91-11-4304-0000 Fax: 91-11-2337-0251 / 0106 E-mail: SearEpidata@who.int, URL:
Vol. 21,
Week 44, 2017
Vaccine Preventable Disease Surveillance Bulletin
Page 2
Table 3: Classification of AFP Cases and Key Surveillance Indicators, 2016-2017 (data as of 06 November 2017)
2016 (Onset)
2017 (Onset)
AFP
Surveillance Indicators
Discarded (Non-polio
AFP)
Total
>90 Days 3
AFP Rate
Non-Polio AFP Rate
% with 2 spec., at least
24 hrs apart, w/in 14
days
0
2.85
2.85
99
100
1 216
0
0
0
1 130
86
12
2.88
2.68
98
99
0
0
5.11
5.11
73
100
7
0
0
0
3
4
1
3.35
1.43
86
100
48
31
17
100
4
Vaccine Derived
Poliovirus Cases
Non-Polio AFP Rate
AFP Rate
>90 Days 3
Total
Vaccine Derived
Poliovirus Cases
Pending
105
0
0
0
105
0
0
1.83
1.83
98
100
79
0
0
0
46 500
0
1
15
46 484
0
0
10.60 10.60
87
98
32 010
0
0
6
Indonesia
1 409
0
0
0
1 409
0
0
2.01
2.01
86
96
1 018
0
0
0
826
192
Maldives
2
0
0
0
2
0
0
2.11
2.11
0
100
4
0
0
0
0
Myanm ar
466
0
0
0
466
0
0
3.38
3.38
96
100
300
0
0
0
Nepal
455
0
0
0
455
0
0
5.24
5.24
96
100
294
0
0
0
Sri Lanka
65
0
0
0
65
0
0
1.20
1.20
85
98
60
0
0
Thailand
246
0
0
0
246
0
0
2.04
2.04
75
98
158
0
Tim or-Leste
10
0
0
0
10
0
0
1.87
1.87
50
80
1
50 706
0
1
15
50 690
0
0
8.38
8.38
87
98
35 147
1.63
0.99
96
8.63
7.74
86
98
109
1.71
1.39
83
98
4
4
5.00
0.00
50
100
273
27
1
2.63
2.39
97
100
279
15
3
4.00
3.80
98
100
0
52
8
1
1.31
1.13
87
100
0
0
127
31
15
1.62
1.30
70
94
0
0
0
0
1
0
0.22
0.00
0
100
0
0
6
6.87
6.15
87
98
28 697 3 307 1 107
31 435 3 706 1 270
1
All countries are using the virologic classification scheme.
2
AFP rates per 100,000 children aged 15 years of age or missing age information are excluded).
3
90 days calculation based on date of paralysis onset subtracted from date of last report received from member countries by SEARO.
2016 India: One type 2 VDPV (iVDPV=1)
[a=ambiguous c=circulating i=immunodeficiency]
4
% with any specimen
Compatible
0
11
Wild Poliovirus Cases
1 437
% with 2 spec., at least
24 hrs apart, w/in 14
days
0
0
4
0
0
Wild Poliovirus Cases
0
0
Pending
India
SEAR
Specim en
AFP Cases
1
% with any specimen
Case Classification
Discarded (Non-polio
AFP)
DPR Korea
Specim en
11
AFP Cases
Bangladesh
2
AFP Rates
1 437
Country
Bhutan
1
Surveillance Indicators
Annualized
AFP Rates 2
Compatible
Case Classification
AFP
Table 4: Intratypic Differentiation (ITD) of Isolates from AFP Cases, 2016-2017 (data as of 06 November 2017)
3
0
0
1
0
0
18
0
0
0
0
0
0
0
0
DPR Korea
NPL, Pyongyong
0
0
8
0
0
0
0
5
5
0
Negative
1
0
Results
pending
NEV
0
0
Vaccine
mixture
NPEV by
PCR
0
1
Vaccine
0
0
Wild
NEV
Negative
0
0
VDPV
Vaccine
3
0
Vaccine
Wild
0
1
Wild
VDPV
8
NIH, Bangkok
Vaccine
Vaccine
IPH, Dhaka
Bhutan
7
Days days
Intratypic Differentiation results
Polio 1
Polio 2
Polio 3
Wild
Wild
Bangladesh
ITD Labs
Vaccine
mixture
NPEV by
PCR
Vaccine
AFP cases
referred
for ITD
2017
Results
pending
Wild
Country of
Case
AFP cases
referred
for ITD
2016
Intratypic Differentiation results
Polio 1
Polio 2
Polio 3
7
days
0
0
BJMC, Ahmedabad
258
0
78
0
25
0
0
74
80
1
0
0
0
0
218
0
77
0
0
0
0
59
76
6
0
0
0
0
NIV, Bengaluru
225
0
56
0
24
0
0
67
70
6
2
0
0
0
143
0
54
0
0
0
0
32
43
14
0
0
0
0
ERC, Mumbai
172
0
53
0
13
0
0
52
43
11
0
0
0
0
141
0
48
0
0
0
0
41
35
15
0
0
2
0
SGPGI, Lucknow
311
0
56
0
53
0
0
86
66
16
34
0
0
0
286
0
59
0
0
0
0
98
62
25
41
0
1
0
KIPM, Chennai
98
0
26
0
17
1
0
26
28
0
0
0
0
0
49
0
9
0
0
0
0
27
13
0
0
0
0
0
NCDC, Delhi
231
0
47
0
38
0
0
91
52
3
0
0
0
0
203
0
56
0
0
0
0
85
53
7
0
0
2
0
IoS, Kolkatta
113
0
26
0
18
0
0
35
33
0
1
0
0
0
162
0
54
0
0
0
0
39
51
15
3
0
0
0
CRI, Kasauli
35
0
5
0
7
0
0
11
12
0
0
0
0
0
20
0
11
0
0
0
0
5
4
0
0
0
0
0
1 443
0
347
0
195
1
0
442
384
37
37
0
0
0
1 222
0
368
0
0
0
0
386
337
82
44
0
5
0
Bio Farma, Bandung
18
0
9
0
3
0
0
1
5
0
0
0
0
0
2
0
0
0
0
0
0
2
0
0
0
0
0
0
NIHRD, Jakarta
12
0
4
0
0
0
0
5
3
0
0
0
0
0
1
0
0
0
0
0
0
0
1
0
0
0
0
0
PHL, Surabaya
13
0
2
0
4
0
0
4
3
0
0
0
0
0
1
0
0
0
0
0
0
1
0
0
0
0
0
0
Indonesia Total
43
0
15
0
7
0
0
10
11
0
0
0
0
0
4
0
0
0
0
0
0
3
1
0
0
0
0
0
Myanm ar
NHL, Yangon
7
0
1
0
1
0
0
2
3
0
0
0
0
0
5
0
1
0
0
0
0
3
1
0
0
0
0
0
Nepal
NIH, Bangkok
6
0
2
0
2
0
0
1
1
0
0
0
0
0
5
0
0
0
0
0
0
3
2
0
0
0
0
0
Sri Lanka
MRI, Colombo
1
0
0
0
0
0
0
1
0
0
0
0
0
0
0
Thailand
NIH, Bangkok
India
India Total
Indonesia
TOTAL
4
0
0
0
0
0
0
2
2
0
0
0
0
0
5
0
2
0
0
0
0
3
0
0
0
0
0
0
1 513
0
368
0
206
1
0
459
404
37
37
1
0
0
1 259
0
379
0
0
0
0
403
346
82
44
0
5
0
Published 06 November 2017
Meetings/ Important events:
Tenth Meeting of the South-East Asia Regional Commission for the Certification of Polio Eradication (SEA-RCCPE), Naypitaw, Myanmar,
23-24 November 2017
Table 1: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2017* (data as of 06 November 2017)
Case classification (number)
Pending classification
Epidemiologicallyconfirmed
Reporti ng
% di s tri cts
ra te of
reporti ng a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
n
non-rubel l a
pop
pop n
na ti ona l
ca s es per
l evel per
100,000 pop n
100,000 pop n
Laboratory-confirmed
Discarded non-measles nonrubella cases
Rubel l a
Clinically-confirmed
% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory
Mea s l es
Epidemiologicallyconfirmed
Number of
s erum
s peci mens
recei ved i n
l a bora tory
% s erum
s peci mens
recei ved a t
l a bora tory
w/i n 5
da ys of
col l ecti on
%
s peci mens
tes ted for
s erol ogy
of
s peci mens
recei ved
i n the
l a bora tory
Laboratory-confirmed
%
s us pected
ca s es wi th
%
Number of a dequa te s us pected
s us pected i nves ti ga ti ca s es wi th
on
mea s l es
s erum
i ni ti a ted s peci mens
ca s es
w/i n 48
col l ected
hours of
noti fi ca ti on
7 418
92
80
5 971
99
100
60
2 491
906
444
209
34
3 334
0
2.53
73
29.10
1.84
221
84
79
166
59
105
46
14
0
0
2
0
160
45
25.38
65
22.20
3.17
DPR Korea
63
100
100
63
100
100
100
0
0
0
0
0
63
0
0.30
0.00
0.00
3
16 200
0
33
5 106
80
85
57
2 326
6 158
0
696
2 004
2 482
2 534
0.23
5
7.92
2.52
4.53
2.60
Countries
Bangladesh
Bhutan
India
4
4 793
38
100
3 531
92
73
27
967
0
0
554
0
497
2 775
0.23
Maldives
62
97
100
62
100
100
69
1
0
0
1
0
59
1
20.40
60
3.46
3.46
Myanmar
1 645
40
88
1 443
99
100
94
994
179
70
3
0
374
25
0.86
14
28.57
0.07
Nepal
713
26
89
232
74
257
84
51
26
21
14
0
571
23
2.47
51
4.24
0.61
Sri Lanka
203
98
89
177
90
100
62
1
0
18
1
0
183
0
1.05
23
62.00
0.42
Thailand
2 381
31
91
2 080
56
96
60
1 281
4
296
23
0
695
82
1.27
28.80
0.42
98
100
99
97
100
87
64
0
0
0
3
0
82
13
8.00
33 797
32
62
18 928
87
92
56
8 126
7 273
849
1 506
2 038
8 500
5 498
0.46
Indonesia
Timor-Leste
SEAR
1
Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases
2
Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases
4
31
A lso includes the cases fro m enhanced measles case-based surveillance.
0.00
2.93
10.30
2.25
ND=No data
3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry
* Figures in the table 1 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.
Table 2: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2016* (data as of 06 November 2017)
Case classification (number)
India 3
4
Pending classification
Discarded non-measles nonrubella cases
Reporting
% di s tri cts
ra te of
reporting a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
n
n
non-rubel l a
pop
pop
na tiona l
ca s es per
l evel per
n
100,000 pop
100,000 pop n
4 298
94
87
3 732
100
100
92
619
354
96
165
0
3 064
0
1.96
80
6.85
1.06
149
63
87
127
59
102
47
10
0
0
0
0
60
79
8.05
55
13.42
0.00
73
100
100
73
100
100
100
0
0
0
0
0
66
7
0.27
0.00
0.00
41 617
0
22
9 037
86
83
31
3 646
12 803
0
1 617
7 539
6 998
9 014
0.55
3
13.00
7.24
10.73
4.50
Epidemiologicallyconfirmed
Laboratory-confirmed
DPR Korea
Rubel l a
Clinically-confirmed
Bhutan
% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory
Mea s l es
Epidemiologicallyconfirmed
Bangladesh
Number of
s erum
s peci mens
recei ved i n
l a bora tory
% s erum
s peci mens
recei ved a t
l a bora tory
w/i n 5
da ys of
col l ection
%
s peci mens
tes ted for
s erol ogy
of
s peci mens
recei ved
i n the
l a bora tory
Laboratory-confirmed
Countries
%
s us pected
ca s es wi th
%
Number of a dequa te s us pected
s us pected i nves tiga ti ca s es wi th
on
s erum
mea s l es
i ni tia ted s peci mens
ca s es
w/i n 48
col l ected
hours of
notifi ca tion
8 107
44
100
5 871
98
74
32
2 705
0
0
1 135
0
2 361
1 906
0.94
Maldives
11
100
100
11
100
0
0
0
0
0
0
0
11
0
3.22
15
0.00
0.00
Myanmar
587
0
86
503
100
99
97
194
59
21
10
0
303
0
0.59
11
5.33
0.19
Indonesia
5
1 079
13
82
1
100
0
137
102
31
22
0
772
15
2.83
56
9.89
0.81
Sri Lanka
339
63
86
291
88
100
68
64
0
48
1
0
226
0
1.09
27
62.00
0.42
Thailand
1 431
25
87
1 096
61
99
58
695
15
239
7
0
415
60
0.64
14.63
0.11
122
75
91
111
100
95
63
2
0
11
9
0
100
0
8.25
46
10.73
7.43
57 813
15
42
20 853
91
89
46
8 072
13 333
446
2 966
7 539
14 376
11 081
0.77
11.72
5.63
Nepal
Timor-Leste
SEAR
1
Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases
4
A lso includes the cases fro m enhanced measles case-based surveillance.
2
Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases
5
So me Lab data variables no t available.
ND=No data
3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry
* Figures in the table 2 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.
Data Sources: Ministries of Health in SEAR Countries.
Published by Immunization & Vaccine Development, World Health Organization, Regional Office for South-East Asia, New Delhi – 110002, India
Tel: 91-11-2337-0804 / 91-11-4304-0000 Fax: 91-11-2337-0251 / 0106 E-mail: SearEpidata@who.int, URL:
Vol. 21,
Week 44, 2017
Vaccine Preventable Disease Surveillance Bulletin
Page 2
Table 3: Classification of AFP Cases and Key Surveillance Indicators, 2016-2017 (data as of 06 November 2017)
2016 (Onset)
2017 (Onset)
AFP
Surveillance Indicators
Discarded (Non-polio
AFP)
Total
>90 Days 3
AFP Rate
Non-Polio AFP Rate
% with 2 spec., at least
24 hrs apart, w/in 14
days
0
2.85
2.85
99
100
1 216
0
0
0
1 130
86
12
2.88
2.68
98
99
0
0
5.11
5.11
73
100
7
0
0
0
3
4
1
3.35
1.43
86
100
48
31
17
100
4
Vaccine Derived
Poliovirus Cases
Non-Polio AFP Rate
AFP Rate
>90 Days 3
Total
Vaccine Derived
Poliovirus Cases
Pending
105
0
0
0
105
0
0
1.83
1.83
98
100
79
0
0
0
46 500
0
1
15
46 484
0
0
10.60 10.60
87
98
32 010
0
0
6
Indonesia
1 409
0
0
0
1 409
0
0
2.01
2.01
86
96
1 018
0
0
0
826
192
Maldives
2
0
0
0
2
0
0
2.11
2.11
0
100
4
0
0
0
0
Myanm ar
466
0
0
0
466
0
0
3.38
3.38
96
100
300
0
0
0
Nepal
455
0
0
0
455
0
0
5.24
5.24
96
100
294
0
0
0
Sri Lanka
65
0
0
0
65
0
0
1.20
1.20
85
98
60
0
0
Thailand
246
0
0
0
246
0
0
2.04
2.04
75
98
158
0
Tim or-Leste
10
0
0
0
10
0
0
1.87
1.87
50
80
1
50 706
0
1
15
50 690
0
0
8.38
8.38
87
98
35 147
1.63
0.99
96
8.63
7.74
86
98
109
1.71
1.39
83
98
4
4
5.00
0.00
50
100
273
27
1
2.63
2.39
97
100
279
15
3
4.00
3.80
98
100
0
52
8
1
1.31
1.13
87
100
0
0
127
31
15
1.62
1.30
70
94
0
0
0
0
1
0
0.22
0.00
0
100
0
0
6
6.87
6.15
87
98
28 697 3 307 1 107
31 435 3 706 1 270
1
All countries are using the virologic classification scheme.
2
AFP rates per 100,000 children aged 15 years of age or missing age information are excluded).
3
90 days calculation based on date of paralysis onset subtracted from date of last report received from member countries by SEARO.
2016 India: One type 2 VDPV (iVDPV=1)
[a=ambiguous c=circulating i=immunodeficiency]
4
% with any specimen
Compatible
0
11
Wild Poliovirus Cases
1 437
% with 2 spec., at least
24 hrs apart, w/in 14
days
0
0
4
0
0
Wild Poliovirus Cases
0
0
Pending
India
SEAR
Specim en
AFP Cases
1
% with any specimen
Case Classification
Discarded (Non-polio
AFP)
DPR Korea
Specim en
11
AFP Cases
Bangladesh
2
AFP Rates
1 437
Country
Bhutan
1
Surveillance Indicators
Annualized
AFP Rates 2
Compatible
Case Classification
AFP
Table 4: Intratypic Differentiation (ITD) of Isolates from AFP Cases, 2016-2017 (data as of 06 November 2017)
3
0
0
1
0
0
18
0
0
0
0
0
0
0
0
DPR Korea
NPL, Pyongyong
0
0
8
0
0
0
0
5
5
0
Negative
1
0
Results
pending
NEV
0
0
Vaccine
mixture
NPEV by
PCR
0
1
Vaccine
0
0
Wild
NEV
Negative
0
0
VDPV
Vaccine
3
0
Vaccine
Wild
0
1
Wild
VDPV
8
NIH, Bangkok
Vaccine
Vaccine
IPH, Dhaka
Bhutan
7
Days days
Intratypic Differentiation results
Polio 1
Polio 2
Polio 3
Wild
Wild
Bangladesh
ITD Labs
Vaccine
mixture
NPEV by
PCR
Vaccine
AFP cases
referred
for ITD
2017
Results
pending
Wild
Country of
Case
AFP cases
referred
for ITD
2016
Intratypic Differentiation results
Polio 1
Polio 2
Polio 3
7
days
0
0
BJMC, Ahmedabad
258
0
78
0
25
0
0
74
80
1
0
0
0
0
218
0
77
0
0
0
0
59
76
6
0
0
0
0
NIV, Bengaluru
225
0
56
0
24
0
0
67
70
6
2
0
0
0
143
0
54
0
0
0
0
32
43
14
0
0
0
0
ERC, Mumbai
172
0
53
0
13
0
0
52
43
11
0
0
0
0
141
0
48
0
0
0
0
41
35
15
0
0
2
0
SGPGI, Lucknow
311
0
56
0
53
0
0
86
66
16
34
0
0
0
286
0
59
0
0
0
0
98
62
25
41
0
1
0
KIPM, Chennai
98
0
26
0
17
1
0
26
28
0
0
0
0
0
49
0
9
0
0
0
0
27
13
0
0
0
0
0
NCDC, Delhi
231
0
47
0
38
0
0
91
52
3
0
0
0
0
203
0
56
0
0
0
0
85
53
7
0
0
2
0
IoS, Kolkatta
113
0
26
0
18
0
0
35
33
0
1
0
0
0
162
0
54
0
0
0
0
39
51
15
3
0
0
0
CRI, Kasauli
35
0
5
0
7
0
0
11
12
0
0
0
0
0
20
0
11
0
0
0
0
5
4
0
0
0
0
0
1 443
0
347
0
195
1
0
442
384
37
37
0
0
0
1 222
0
368
0
0
0
0
386
337
82
44
0
5
0
Bio Farma, Bandung
18
0
9
0
3
0
0
1
5
0
0
0
0
0
2
0
0
0
0
0
0
2
0
0
0
0
0
0
NIHRD, Jakarta
12
0
4
0
0
0
0
5
3
0
0
0
0
0
1
0
0
0
0
0
0
0
1
0
0
0
0
0
PHL, Surabaya
13
0
2
0
4
0
0
4
3
0
0
0
0
0
1
0
0
0
0
0
0
1
0
0
0
0
0
0
Indonesia Total
43
0
15
0
7
0
0
10
11
0
0
0
0
0
4
0
0
0
0
0
0
3
1
0
0
0
0
0
Myanm ar
NHL, Yangon
7
0
1
0
1
0
0
2
3
0
0
0
0
0
5
0
1
0
0
0
0
3
1
0
0
0
0
0
Nepal
NIH, Bangkok
6
0
2
0
2
0
0
1
1
0
0
0
0
0
5
0
0
0
0
0
0
3
2
0
0
0
0
0
Sri Lanka
MRI, Colombo
1
0
0
0
0
0
0
1
0
0
0
0
0
0
0
Thailand
NIH, Bangkok
India
India Total
Indonesia
TOTAL
4
0
0
0
0
0
0
2
2
0
0
0
0
0
5
0
2
0
0
0
0
3
0
0
0
0
0
0
1 513
0
368
0
206
1
0
459
404
37
37
1
0
0
1 259
0
379
0
0
0
0
403
346
82
44
0
5
0